Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation

Table 2

Measurements of renal function at month 6.

	$n$	Tacrolimus/Sirolimus $N=318$	$n$	Tacrolimus/MMF $N=316$
Creatinine Clearance (Cockcroft-Gault), mean (SE), mL/min
Patients completing the study	250	66.4 (1.4)	266	65.2 (1.3)
Patients with month 6 ${\text{data}}^{\text{a}}$	289	64.6 (1.3)	289	63.7 (1.3)
Patients with DGF	48	56.1 (20.0)	38	60.5 (22.9)
Patients without DGF	241	66.3 (21.5)	251	64.2 (21.9)
Creatinine Clearance (MDRD-4), mean (SD), mL/min
Patients completing the study	250	55.3 (1.2)	266	54.0 (1.2)
Patients with month 6 ${\text{data}}^{\text{a}}$	289	53.9 (1.1)	289	53.0 (1.2)
Serum Creatinine, mean, (SD), $\mu$mol/L
Patients completing the study	250	133.9 (51.4)	266	137.2 (52.7)
Patients with month 6 ${\text{data}}^{\text{a}}$	289	138.2 (57.7)	289	144.7 (93.7)
Patients with DGF	48	169.9 (77.0)	38	151.5 (54.8)
Patients without DGF	241	131.9 (51.0)	251	143.7 (98.3)

FAS
DGF: Delayed graft function. MDRD: Modification of Diet in Renal Disease.
${}_{}{}^{\text{a}}\text{Completers}$ and withdrawn patients with available data at 6 months after transplantation.